Which phase of clinical research is Zenocutuzumab currently in?

Zenocutuzumab is a targeted therapeutic antibody against the NRG1 gene fusion. It is mainly used to treat patients with advanced solid tumors carrying this gene fusion. According to the latest information in 2025, zetolizumab has currently completed I and II clinical trials, and has received accelerated approval from the U.S. Food and Drug Administration (FDA) based on the results of these trials. This marks an important progress in the clinical development of zetolizumab and provides new treatment hope for relevant patients.

The clinical trials of zetolizumab are mainly focused on two types of tumors carrying NRG1 fusions: non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). I/IIThe results of the phase I/II trial showed that zetolizumab showed good anti-tumor activity in these patients, with most patients experiencing significant tumor shrinkage and being well tolerated. These positive effects have moved the drug toward larger clinical trials and the approval process.

Currently, zetolizumab has not been officially launched in mainland China, and domestic patients are temporarily unable to obtain the drug through conventional channels. However, with the approval of the FDA and the continuous accumulation of clinical data, zetolizumab is expected to enter the Chinese market in the future, bringing new treatment options to patients with advanced solid tumors carrying the NRG1 fusion gene. Patients and doctors can follow the latest developments of the drug and keep abreast of launch information.

In general, zetolizumab has completed I/II phase clinical trials, and has been approved by FDA for accelerated marketing, and is in a rapid development stage. In the future, with the release of more clinical research data and the advancement of the approval process, zetolizumab is expected to become an important targeted drug for NRG1 fusion-related tumors. Patients should choose a treatment plan rationally under the guidance of a professional doctor and combined with the latest information, and look forward to the therapeutic breakthroughs brought by this drug.

Reference materials:https://www.drugs.com/